Back to Report Store Home

Global Cardiovascular Disease Drugs Market to 2023 – Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

  • Published: Dec-2017
  • Report Code: GBIHC461MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 11

2.1 Therapy Area Introduction 11

2.2 Symptoms 12

2.3 Diagnosis 13

2.3.1 Hypertension 13

2.3.2 Dyslipidemia 14

2.3.3 Imaging Tests 15

2.3.4 Stress Testing 15

2.4 Etiology, Pathophysiology, Comorbidities and Complications 16

2.4.1 Hypertension 17

2.4.2 Dyslipidemia 19

2.4.3 Heart Failure 21

2.4.4 Thrombosis 21

2.5 Epidemiology Patterns and Forecasts – Prevalence and Patient Segmentation 23

2.5.1 Hypertension 23

2.5.2 Dyslipidemia 24

2.5.3 Heart failure 25

2.5.4 Thrombotic events 26

2.6 Prognosis 26

2.7 Management and Treatment of Cardiovascular Disease 27

2.7.1 Pharmacological Intervention 27

2.7.2 Non-pharmacological Intervention 35

2.7.3 Unmet Need 35

3 Key Marketed Products 37

3.1 Overview 37

3.2 Lipitor (atorvastatin) – Pfizer 38

3.3 Crestor (rosuvastatin) – AstraZeneca 39

3.4 Zetia (ezetimibe) – Merck & Co. 40

3.5 Praluent (alirocumab) – Sanofi 42

3.6 Repatha (evolocumab) – Amgen 43

3.7 Plavix (clopidogrel) – Sanofi 44

3.8 Xarelto (rivaroxaban) – Bayer 45

3.9 Eliquis (apixaban) – Bristol Myers Squibb and Pfizer 47

3.10 Brilinta (ticagrelor) – AstraZeneca 48

3.11 Entresto (valsartan plus sacubitril) – Novartis 50

3.12 Benicar (olmesartan medoxomil) – Daiichi Sankyo 51

3.13 Bevyxxa (betrixaban) – Portola 52

3.14 Uptravi (selexipag) – Johnson & Johnson 53

3.15 Opsumit (macitentan) – Johnson & Johnson 55

3.16 Conclusion 56

4 Pipeline Landscape Assessment 59

4.1 Overview 59

4.2 Pipeline Development Landscape 60

4.3 Molecular Targets in the Pipeline 63

4.4 Clinical Trials 67

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 68

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 72

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 76

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 80

4.4.5 Assessment of Key Pipeline Products 84

4.5 Conclusion 93

5 Multi-Scenario Market Forecast to 2023 95

5.1 Overall Market Size 95

5.2 Generic Penetration 99

5.3 Revenue Forecast by Molecular Target 102

5.3.1 Coagulation Cascade 103

5.3.2 Renin angiotensin system 104

5.3.3 P2Y12 Receptors 105

5.3.4 HMG-CoA Reductase Inhibitors (statins) 106

5.3.5 PCSK9 Inhibitors 107

5.3.6 Beta 1 Adrenergic Receptors 108

5.3.7 Prostaglandin Receptors 109

5.3.8 Endothelin Receptors 110

6 Company Analysis and Positioning 111

6.1 Revenue and Market Share Analysis by Company 113

6.2 Company Landscape 125

6.3 Marketed and Pipeline Portfolio Analysis 125

7 Strategic Consolidations 128

7.1 Licensing Deals 128

7.1.1 Deals by Region, Value and Year 128

7.1.2 Deals by Indication 130

7.1.3 Deals by Stage of Development and Value 131

7.1.4 Deals by Molecule Type, Molecular Target and Value 132

7.1.5 List of Deals with Disclosed Deal Values 133

7.2 Co-development Deals 134

7.2.1 Deals by Region, Year and Value 134

7.2.2 Deals by Indication 136

7.2.3 Deals by Stage of Development and Value 137

7.2.4 Deals by Molecule Type, Molecular Target and Value 138

7.2.5 List of Deals with Disclosed Deal Values 139

8 Appendix 140

8.1 References 140

8.2 Tables of All Pipeline Products 146

8.3 Abbreviations 224

8.4 Disease List 225

8.4.1 Hypertension 225

8.4.2 Dyslipidemia 225

8.4.3 Heart failure 225

8.4.4 Thrombotic events 225

8.4.5 Other 225

8.5 Methodology 226

8.5.1 Coverage 226

8.5.2 Secondary Research 226

8.5.3 Market Size and Revenue Forecasts 227

8.5.4 Pipeline Analysis 227

8.5.5 Competitive Landscape 227

8.6 Contact Us 228

8.7 Disclaimer 228

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards